To identify novel indicators for colorectal cancer (CRC) metastasis and prognosis, we previously conducted gene expression array analysis using clinical samples resulting in the identification of several genes, which are involved in cancer progression and metastasis ([@bib34]). The candidate genes include the *PVT-1* oncogene (*PVT-1*), which encodes a long noncoding RNA (lncRNA) and maps to chromosome 8q24 (8q24) ([@bib8]; [@bib2]; [@bib12]). Amplification of 8q24 is one of the most frequent events in a wide variety of malignant diseases including CRC, and has been associated with reduced survival duration in several studies ([@bib28]; [@bib20]; [@bib11]). In addition to *PVT-1*, the well-established oncogene *MYC* has also been mapped to 8q24, and these two genes are co-amplified in CRC cell lines ([@bib32]).

lncRNAs were previously believed to represent random transcriptional noise. However, their expression levels have been observed to vary spatially, temporally and in response to various stimuli ([@bib24]; [@bib27]). Moreover, several lncRNAs exhibit very precise expression patterns in different tissues ([@bib3]; [@bib25]). In spite of emerging evidence, our understanding of the functions of these lncRNAs is limited. *PVT-1* produces a wide variety of spliced noncoding RNAs as well as a cluster of six annotated microRNAs: *miR-1204*, *miR-1205*, *miR-1206*, *miR-1207-5p*, *miR-1207-3p* and *miR-1208* ([@bib5]). However, *PVT-1* exerts its influence as an lncRNA ([@bib11]; [@bib1]; [@bib37]). The molecular mechanism of *PVT-1* transcripts in gene regulation remains unclear. In the current study, we investigated the clinical significance of *PVT-1* expression in CRC.

Materials and methods
=====================

Patients and sample collection
------------------------------

We used a total of 312 CRC samples, of which 148 (set 1) were used as pure cancer tissues separated by laser microdissection (all cases were used for gene expression array and 130 cases were used for array-CGH), and 164 (set 2) were used in bulk for quantitative reverse transcription--PCR. All samples were obtained during surgery from patients who underwent resection of the primary tumour at Kyushu University Hospital at Beppu and affiliated hospitals between 1992 and 2007. Written informed consent was obtained from all patients. All patients had a clear histological diagnosis of CRC and were closely followed up every 3 months. The follow-up period in set 1 ranged from 0.1 months to 3.2 years with a mean of 2.1 years; follow-up in set 2 ranged from 0.1 to 12.3 years, with a mean of 3.8 years. Resected cancer tissues were immediately cut and stored in RNAlater (Ambion, Palo Alto, CA, USA) or embedded in Tissue-Tek OCT (optimum cutting temperature) medium (Sakura, Tokyo, Japan), frozen in liquid nitrogen and kept at −80 °C until DNA and RNA extraction. For DNA extraction, the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) was used following the manufacturer\'s protocol. For RNA extraction, frozen tissue specimens were homogenised in guanidinium thiocyanate, and total RNA was obtained by ultracentrifugation through a caesium chloride cushion. cDNA for reverse transcription--PCR was synthesised from 8.0 *μ*g of total RNA with M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Clinicopathological factors and clinical stage were classified using the TNM system of classification. All sample data, including age, gender, histology, tumour depth, lymph node metastasis, lymphatic invasion, vascular invasion, liver metastasis and postoperative liver recurrence, were obtained from the clinical and pathological records.

Laser microdissection
---------------------

Tissue samples were microdissected using an LMD6000 laser microdissection system (Leica Laser Microdissection System; Leica Microsystems, Wetzlar, Germany). For LMD, 5 *μ*m-thick frozen sections were fixed in 70% ethanol for 30 s, stained with hematoxylin and eosin and de-hydrated as follows: 5 s each in 70%, 95% and 100% ethanol. Sections were air dried and then microdissected with the LMD system. Target cells were excised, with at least 100 cells per section, and bound to the transfer film. Total RNA was then extracted.

Quantitative real-time reverse transcription--PCR
-------------------------------------------------

For quantitative real-time reverse transcription (qRT)--PCR, *PVT-1* (NR_003367.1) primer sequences were 5′-TGAGAACTGTCCTTACGTGACC-3′ and 5′-AGAGCACCAAGACTGGCTCT-3′, and *MYC* (NM_002467.4) primer sequences were 5′-CACCAGCAGCGACTCTGA-3′ and 5′-GATCCAGACTCTGACCTTTTGC-3′. To normalise for RNA concentration, glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) served as an internal control. The sequences of the *GAPDH* primers were sense, 5′-TTGGTATCGTGGAAGGACTCA-3′ and antisense, 5′-TGTCATCATATTTGGCAGGTT-3′. The amplification protocol included an initial denaturation step at 95 °C for 10 min, followed by 45 cycles of 95 °C for 10 s and 60 °C for 30 s. qRT--PCR was performed in a LightCycler 480 instrument (Roche Applied Science, Basel, Switzerland) using the LightCycler 480 Probes Master kit (Roche Applied Science). All concentrations were calculated relative to the concentration of cDNA using Human Universal Reference Total RNA (Clontech, Palo Alto, CA, USA). The concentration of *PVT-1* was then divided by the concentration of the endogenous reference (*GAPDH*) to obtain normalised expression values. For qRT--PCR, for *miR-1204*, *miR-1205*, *miR-1206*, *miR-1207-3p*, *miR-1207-5p* and *miR-1208*, cDNA was synthesised from total RNA using TaqMan MicroRNA specific primers for each microRNAs (Applied Biosystems, Foster City, CA, USA) and a TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). Expression of target miRNAs was normalised to the expression of a small nuclear RNA, *RNU6B* (Applied Biosystems).

Cell lines
----------

The human colorectal cancer cell lines RKO and HCT116 were obtained from the Japanese Cancer Research Bank (Tokyo, Japan) and maintained in Dulbecco\'s modified Eagle\'s medium containing 10% fetal bovine serum, 100 units ml^−1^ penicillin and 100 *μ*g ml^−1^ streptomycin sulphate. All cells were cultured in a humidified 5% CO~2~ incubator at 37 °C.

PVT-1 siRNA transfection
------------------------

*PVT-1*-specific siRNAs (*PVT-1*siRNA-1: sense GCUUGGAGGCUGAGGAGUUTT and antisense AACUCCUCAGCCUCCAAGCTT and *PVT-1* siRNA-2: sense CCCAACAGGAGGACAGCUUTT and antisense AAGCUGUCCUCCUGUUGGGTT) and negative control siRNA were purchased from Cosmo Bio (Tokyo, Japan). siRNA oligonucleotide (30 nmol l^−1^) in Opti-MEM (Invitrogen) were transfected into RKO and HCT116 cells using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer\'s protocol. Cells in logarithmic growth phase were diluted without antibiotics and were seeded at 2 × 10^5^ or 5 × 10^4^ cells per well in a final volume of 2 ml or 500 *μ*l, respectively, in 6- or 24-well flat-bottom microtiter plates, respectively. The cells were incubated in a humidified atmosphere (37 °C and 5% CO~2~) for 24 h before use in assays.

Cell proliferation assay and cell invasion assay
------------------------------------------------

To conduct the cell proliferation assay, 10 *μ*l of MTT-labelling reagent (at a final concentration of 0.5 mg ml^−1^) was added to each well, and the plate was incubated for 4 h in a humidified atmosphere. Solubilisation solution (100 *μ*l) was added to each well, and the plate was incubated overnight in a humidified atmosphere. After confirming that the purple formazan crystals were completely solubilised, the absorbance of each well was measured using a Model 550 series microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) at a wavelength of 570 nm corrected to 655 nm. The assay was performed using six replicates.

Invasion assays were done using the BD Biocoat Matrigel Invasion Chamber (pore size: 8 *μ*m, 24-well; BD Biosciences, San Jose, CA, USA) following the manufacturer\'s protocol. A total of 5 × 10^4^ cells were plated in the upper chamber in serum-free medium. The bottom chamber contained medium with 10% FBS. After 72 h, the bottom of the chamber insert was stained with Calcein AM (Invitrogen). The cells that had invaded through the membrane to the lower surface were evaluated in a fluorescence plate reader at excitation/emission wavelengths of 485/530 nm. Each assay was conducted in at least three replicates.

Western blotting
----------------

Total protein was extracted from each cell line. Aliquots of total protein (40 *μ*g) were electrophoresed in 10% concentrated poly-acrylamide gel and then electrophoresed and then electroblotted as previously described ([@bib14]). The primary mouse monoclonal antibodies against caspase 3 (Cell Signaling Technology, Danvers, MA, USA), SMAD4 (Santa Cruz Biotechnbology, Dallas, TX, USA) were used at a dilution of 1 : 1000 and 1 : 200, respectively. Primary antibodies were detected using horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare Japan, Tokyo, Japan) and the ImageQuant LAS 4000mini system (GE Healthcare Japan). Caspase 3 and SMAD4 proteins were normalised to the level of *β*-tubulin protein (Cell Signaling Technology) diluted 1 : 1000.

Array-CGH and copy-number analysis
----------------------------------

A total of 130 tumour samples were prepared for array-CGH analysis. For genome profiling, the labelling and hybridisation of genomic DNA onto the Agilent Human Genome Microarray Kit 244 K (Agilent Technologies, Santa Clara, CA, USA) were performed according to the manufacturer\'s instructions. The raw signal intensities were measured and transformed into log ratios to reference DNA with 'Feature Extraction\' software (version 9.1) from Agilent Technologies. Arrays were analysed using the Agilent DNA microarray scanner. The log ratio was thereafter used as the signal intensity of each probe. The raw copy-number data for each sample provided by array CGH was analysed using the GISTIC algorithm ([@bib6]; [@bib26]).

Gene expression array
---------------------

The commercially available whole-Human Genome Microarray Kit and SurePrint G3 Human GE Microarray Kit (Agilent Technologies) were used to investigate globally altered genes. In brief, cyanine-labelled cRNA was prepared using the T7 linear amplification technique described in the Agilent Low RNA Input Fluorescent Linear Amplification Kit Manual (Agilent Technologies). Hundred nanograms of total RNA was extracted using the LMD technique and reverse transcribed to generate double-stranded cDNA using an oligo dT T7 promoter primer. Subsequently, cRNA was synthesised using T7 RNA polymerase, which simultaneously incorporated Cy3-labelled CTP. The quality of the cRNA was verified with the Agilent Bioanalyzer 2100. One microgram aliquots of Cy3-labelled cRNA were combined and fragmented in a hybridisation cocktail (Agilent Technologies). Labelled cRNA was then fragmented and hybridised to an oligonucleotide microarray. Fluorescence intensities were determined with an Agilent DNA microarray scanner. The gene expression profiles obtained from microarray data were quantile normalised. The batch effect in microarray experiments was also adjusted by an empirical Bayesian approach ([@bib17]).

Gene set enrichment analysis
----------------------------

For GSEA, *PVT-1* expression was treated as a numeric variable. We applied a continuous-type CLS file of the *PVT-1* profile to phenotype labels in GSEA. The metric for ranking genes in GSEA was set as 'pearson,\' and the other parameters were set to their default values ([@bib33]).

Statistical analysis
--------------------

For continuous variables, data were expressed as means±s.d. The relationship between *PVT-1* expression and clinicopathological factors was analysed using a χ^2^-test and Student\'s *t*-test. Findings were considered significant when the *P*-value was \<0.05. Correlation coefficients were analysed using the Pearson product-moment correlation coefficient. All tests were performed using the JMP software (SAS Institute Inc., Cary, NC, USA).

Results
=======

8q24 copy-number amplification and *PVT-1* expression
-----------------------------------------------------

First, we applied array-CGH and gene expression array analyses on 130 CRC tumours to investigate the correlation between chromosome 8q24 copy-number and *PVT-1* expression, and significant correlation was observed ([Figure 1A](#fig1){ref-type="fig"}; *R*^2^=0.181, *P*\<0.0001). This result was validated with the Cancer Cell Line Encyclopedia (CCLE, <http://www.broadinstitute.org/ccle/home>), which is a recently compiled public resource that contains gene expression and chromosomal copy-number data from nearly 1000 cancer cell lines([@bib4]). A significant positive correlation between 8q24 copy-number and *PVT-1* expression was also observed in 50 CRC cell lines ([Figure 1B](#fig1){ref-type="fig"}; *R*^2^=0.420, *P*\<0.0001). These findings showed that 8q24 copy-number gain promoted *PVT-1* expression and suggested that aberrant expression of *PVT-1*, which we previously identified to be a candidate gene for CRC metastasis and progression ([@bib34]), was of significance accompanied by genomic alteration in CRC. As *MYC* is a well-established oncogene, which also maps to 8q24, we investigated the correlation between 8q24 copy-numbers and *MYC* expression. Copy-numbers of 8q24 and *MYC* expression were also positively correlated in CRC tissues and CRC cell lines. However, the correlation between *MYC* and 8q24 copy-numbers was weaker than that between *PVT-1* and 8q24 copy-numbers ([Figures 1C and D](#fig1){ref-type="fig"}).

Knockdown of *PVT-1* promotes apoptosis in colorectal cancer cell lines
-----------------------------------------------------------------------

Next, we conducted *PVT-1* knockdown assays using siRNA to investigate the biological function of *PVT-1* transcripts in CRC cells. Using qRT--PCR, we confirmed that *PVT-1* expression in RKO and HCT116 cells transfected with *PVT-1*-specific siRNA was significantly lower than that in cells transfected with the negative control siRNA ([Figure 2A](#fig2){ref-type="fig"}). Cell proliferation assays were carried out in RKO and HCT116 colorectal cancer cells transfected with *PVT-1* siRNA or negative control siRNA. Both RKO and HCT116 cell lines have 8q24 copy-number amplification and *PVT-1* upregulation according to the CCLE database. *PVT-1* knockdown significantly inhibited cancer cell proliferation in both cell lines ([Figure 2B](#fig2){ref-type="fig"}). This finding suggested that aberrant expression of *PVT-1* promoted the cell proliferation capability of colorectal cancer cells. Next, we conducted cancer cell invasion assays to verify the effect of *PVT-1* on metastasis, since we had originally identified *PVT-1* as a metastasis regulating gene. Then we observed that *PVT-1* siRNA transfected cells had reduced invasive abilities compared with negative control cells ([Figure 2C](#fig2){ref-type="fig"}).

To uncover the underlying mechanisms of anticancer activity of *PVT-1* knockdown, we performed gene expression microarray assays on cells transfected with *PVT-1* siRNA and negative control siRNA. A total of 649 genes including several apoptosis-relating genes were upregulated and 538 genes including some oncogenes were downregulated by *PVT-1* knockdown ([Figure 2D](#fig2){ref-type="fig"}, [Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"}). Functional annotation analyses were performed using David Bioinformatics Resources 6.7, which is a web-based bioinformatics application (<http://david.abcc.ncifcrf.gov/>) ([@bib15]), and we found that genes in the pathways for transforming growth factor beta (TGF-*β*) signalling and apoptosis were activated in cells with *PVT-1* knockdown ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Actually, western blot analyses showed that the protein expression of SMAD4, which is in the TGF-*β* signalling pathway, was induced, and the cleavage of caspase 3 was observed in *PVT-1* knockdown cells ([Figure 2E](#fig2){ref-type="fig"}). These data showed that apoptosis was induced to CRC cells transfected with *PVT-1* siRNA via activation of TGF-*β* signalling. In order to confirm whether apoptosis was induced by knockdown of *PVT-1* lncRNA or by knockdown of microRNAs encoded by *PVT-1*, which seemed to be downregulated following knockdown of *PVT-1* transcripts, we conducted qRT--PCR assays for these six microRNAs in CRC cells transfected with *PVT-1* siRNA and negative control siRNA. Five of six microRNAs were detected by qRT--PCR, and no microRNAs were downregulated by *PVT-1* knockdown in CRC cells ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

*PVT-1* expression is a prognostic indicator for colorectal cancer patients
---------------------------------------------------------------------------

*PVT-1* expression levels in 164 tumour tissues and corresponding normal tissues were examined by qRT--PCR to investigate the clinical significance of *PVT-1* in CRC. *PVT-1* expression levels in cancerous tissues were significantly higher than those in non-cancerous tissues (*P*\<0.0001; [Figure 3A](#fig3){ref-type="fig"}). We divided the 164 patients with CRC into a high *PVT-1* expression group (*n*=131) and a low *PVT-1* expression group (*n*=33), classified as having expression levels higher or lower than the 20 percentile value, respectively, which is an approximation of the highest value among normal tissues. Clinicopathological factors were then analysed in the high and low *PVT-1* expression groups ([Table 1](#tbl1){ref-type="table"}). The high *PVT-1* expression group showed greater lymph node metastasis and venous invasion compared with the low *PVT-1* expression group. With regard to overall survival, patients with high *PVT-1* expression had a significantly poorer prognosis than those with low *PVT-1* expression (*P*=0.0101; [Figure 3B](#fig3){ref-type="fig"}). Univariate and multivariate analysis showed that *PVT-1* expression level was an independent prognostic indicator of overall survival in patients with CRC (relative risk: 2.532, *P*=0.016; [Table 2](#tbl2){ref-type="table"}). The clinical significance of *MYC* expression was also investigated in the same 164 colorectal cancer cases, as *MYC* is another important oncogene that maps to 8q24. *MYC* expression levels in cancerous tissues were significantly higher than those in non-cancerous tissues (*P*\<0.0001; [Figure 3C](#fig3){ref-type="fig"}). In addition, we analysed the impact of *MYC* expression on colorectal cancer patients. We divided the 164 patients with colorectal cancer into a high *MYC* expression group (*n*=98) and a low *PVT-1* expression group (*n*=66), classified as having expression levels higher or lower than the 40 percentile value, respectively, which is an approximation of the highest *MYC* expression value among normal tissues. However, the significance of *MYC* as a prognosticator for overall survival was not demonstrated in this case set ([Figure 3D](#fig3){ref-type="fig"}).

Discussion
==========

Several published reports have revealed that *PVT-1* is involved in cancer pathophysiology. In the current study, we focused on the clinical significance of aberrant *PVT-1* expression caused by copy-number amplification of chromosome 8q24. The *MYC* oncogene is also a notable oncogene mapping to 8q24 ([@bib28]; [@bib20]; [@bib11]). However, the prognostic value of *MYC* expression was not verified in our case set. Although these data do not contradict the previously demonstrated significance of the *MYC* oncogene, the meaning of *PVT-1* in CRC pathophysiology was strongly suggested.

In our gene expression microarray analysis of CRC cell lines ([Figure 2D](#fig2){ref-type="fig"}), genes relating to the TGF-*β* signalling pathway were upregulated by *PVT-1* knockdown. *SMAD4,* a well-known tumour suppressor gene, is a major mediator of intracellular TGF-*β* signalling ([@bib13]; [@bib23]) and inhibits tumour growth by inducing apoptosis in cancer cells ([@bib7]; [@bib9]; [@bib16]; [@bib21]). In the current study, *SMAD4* and apoptosis-relating genes were upregulated by *PVT-1* knockdown, suggesting that *PVT-1* knockdown promoted apoptosis via TGF-*β* signalling activation in CRC cells. On the other hand, *ROCK1*, which is another mediator of TGF-*β* signalling and promotes cancer invasiveness, was also activated in *PVT-1* knockdown cells. However, *PVT-1* knockdown cells lose their invasive capability ([Figure 2B](#fig2){ref-type="fig"}). We consider that this is because apoptosis has more impact on the phenotypes of CRC cells than *ROCK1* activation. Guan *et al*, have reported that *PVT-1* inhibits apoptosis independently of *MYC* in breast and ovarian cancer ([@bib11]), and our results support their findings. However, the functions of microRNAs encoded by *PVT-1* must be taken into account. *miR-1207-5p* was an only microRNA deregulated by *PVT-1* knockdown, and the expression level of *miR-1207-5p* was upregulated following *PVT-1* knockdown ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). *miR-1207-5p* was predicted to repress *CASP9*, using the microRNA target prediction online tool, TargetScan (<http://www.targetscan.org/>), which is involved in apoptosis signal and is one of the representative genes deregulated by *PVT-1* knockdown (shown in [Figure 3D](#fig3){ref-type="fig"}). Namely, *miR-1207-5p* was thought to inhibit apoptosis. Therefore, we consider that these microRNAs are regulated by other transcriptional mechanism and that these microRNAs are not involved in apoptosis induced by *PVT-1* knockdown.

Although only a small number of functional lncRNAs have been well characterised to date, emerging evidence has suggested that lncRNAs have roles as drivers of tumour suppressive or oncogenic functions in a wide variety of cancer types. In addition, many researchers have suggested mechanisms of action underlying the regulation of gene expression by lncRNAs ([@bib36]). For example, lncRNAs can regulate chromosome structure *in cis* ([@bib18]) or *in trans* ([@bib29]; [@bib19]). Other lncRNAs modulate the activity of protein-binding partners ([@bib10]; [@bib22]). However, the molecular function of *PVT-1* is still controversial. However, we speculate that *PVT-1* regulates chromatin modification by targeting the SWItch/Sucrose NonFermentable (SWI/SNF) complex, which has tumour suppressive function ([@bib30]; [@bib35]). GSEA on clinical CRC samples suggested that *PVT-1* modulated the expression levels of target genes of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (*SMARCA2*) that constitute an ATPase subunit of SWI/SNF complex ([Supplementary Figures S2A and B](#sup1){ref-type="supplementary-material"}) and that *PVT-1* was associated with the apoptosis pathway ([Supplementary Figures S2C](#sup1){ref-type="supplementary-material"}). In addition, Shen *et al.* have reported the positive correlation between the expression of *SMARCA2, SMAD4* and other genes on the TGF-*β* pathway ([@bib31]). Our *in vitro* study also supported these findings ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). However, a limitation of this current study is that we did not demonstrate a direct molecular function of *PVT-1* in apoptosis induction clearly, and further investigation is needed.

In summary, we demonstrated that *PVT-1*, which encodes an lncRNA and maps to 8q24, generates antiapoptotic activity in colorectal cancer cells and that abnormal expression of *PVT-1* was a prognostic indicator for colorectal cancer patients. Further study is required to understand the underlying mechanism of apoptosis inhibition by *PVT-1*.
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![**Positive correlation between chromosome 8q24 copy-number and *PVT-1* or *MYC* expression.** (**A**) Chromosome 8q24 copy-number (horizontal axis) and *PVT-1* expression (vertical axis) analysed by array-CGH and gene expression array in 130 colorectal cancer cases. Dot plots indicate each case. (**B**) Chromosome 8q24 copy-number (horizontal axis) and *PVT-1* expression (vertical axis) in 50 colorectal cancer cell lines (the Cancer Cell Line Encyclopedia database). Dot plots indicate each cell line. (**C**) Chromosome 8q24 copy-number (horizontal axis) and *MYC* expression (vertical axis) analysed by array-CGH and gene expression array in 130 colorectal cancer cases. Dot plots indicate each case. (**D**) Chromosome 8q24 copy-number (horizontal axis) and *MYC* expression (vertical axis) in 50 colorectal cancer cell lines (the CCLE database). Dot plots indicate each cell line.](bjc2013698f1){#fig1}

![**Knockdown of *PVT-1* promoted apoptosis in colorectal cancer cells.** (**A**) qRT--PCR analysis showed that PVT-1 expression levels of both cell lines transfected with *PVT-1* siRNA were significantly lower than negative control (nc) cells. (**B**) Cell proliferation ratio of RKO cells (*left panel*) and HCT116 cells (*right panel*) with or without *PVT-1* knockdown. (**C**) Invasive properties of RKO cells (*left panel*) and HCT116 cells (*right panel*) with or without *PVT-1* knockdown. (**D**) A total of 1187 genes with significant alteration of expression levels (649 upregulated and 538 downregulated) by knockdown of *PVT-1*(*P*\<0.05). Representative genes are shown in the right side of the heat map. (**E**) Western blot (left, RKO; right, HCT116) analyses of cells transfected with *PVT-1* siRNA, and negative control cells show the activation of SMAD4 and cleavage of caspase3. Histograms represent the means±s.d. of three independent experiments. nc, cells transfected with negative control siRNA. si-1, cells transfected with *PVT-1* siRNA-1. si-2, cells transfected with *PVT-1* siRNA-2. \*, statistically significant (*P*\<0.05).](bjc2013698f2){#fig2}

![**Abundant *PVT-1* expression is involved in poor prognosis in colorectal cancer.** (**A**) qRT--PCR analyses of *PVT-1*expression levels on tumour tissues and paired normal tissues from 164 colorectal cancer samples. (**B**) Kaplan--Meier overall survival curves for 164 patients with CRC classified according to *PVT*-*1* expression level. (**C**) qRT--PCR analyses of *MYC* expression levels on tumour tissues and paired normal tissues from 164 colorectal cancer samples. (**D**) Kaplan--Meier overall survival curves for 164 patients with CRC classified according to *MYC* expression level.](bjc2013698f3){#fig3}

###### PVT-1 expression and clinicopathological factors in 164 colorectal cancer cases

                                              **Low expression**   **High expression**                 
  -------------------------- --------------- -------------------- --------------------- ----- -------- -----------------------------------
  Age (y)                         \<65                10                 30.30%          48    36.64%                0.4922
                                  \>66                23                 69.70%          83    63.36%                    
  Sex                             Male                19                 57.58%          78    59.54%                0.8375
                                 Female               14                 42.42%          53    40.46%                    
  Histological grade          Well/moderate           31                 93.94%          121   92.37%                0.7514
                                  other               2                   6.06%          10    7.63%                     
  Tumour size                    \<30 mm              7                  21.21%          33    25.19%                0.6303
                                 ⩾30 mm               26                 78.79%          98    74.81%                    
  Serosal invasion               Absent               12                 36.36%          36    27.48%                0.3236
                                 Present              21                 63.64%          95    72.52%                    
  Lymph node metastasis            N0                 24                 72.73%          62    47.33%   0.0079[a](#t1-fn2){ref-type="fn"}
                                  N1-2                9                  27.27%          69    52.67%                    
  Lymphatic invasion             Absent               24                 72.73%          73    55.73%                0.0702
                                 Present              9                  27.27%          58    44.27%                    
  Venous invasion                Absent               30                 90.91%          100   76.34%   0.0472[a](#t1-fn2){ref-type="fn"}
                                 Present              3                   9.09%          31    23.66%                    
  Liver metastasis               Absent               32                 96.97%          114   87.02%                0.0649
                                 Present              1                   3.03%          17    12.98%                    
  Peritoneal dissemination       Absent               33                 100.00%         123   93.89%                0.0545
                                 Present              0                   0.00%           8    6.11%                     
  Distant metastasis             Absent               32                 96.97%          128   97.71%                0.8104
                                 Present              1                   3.03%           3    2.29%                     
  UICC Stage                    0, I, II              24                 72.73%          57    43.51%   0.0023[a](#t1-fn2){ref-type="fn"}
                                 III, IV              9                  27.27%          74    56.49%                    

Abbreviations: Moderate=moderately differentiated tubular adenocarcinoma; UICC=Union for International Cancer Control; Well=well differentiated tubular adenocarcinoma.

Statistically significant.

###### Univariate and multivariate analysis for overall survival (Cox proportional hazards regression model)

                                        **Univariate analysis**    **Multivariate analysis**                                                               
  ------------------------------------- ------------------------- --------------------------- ------------------------------------ ------- --------------- ----------------------------------
  Age (\< 65/66 \<)                     0.646                           −0.800-- −0.083       0.016[a](#t2-fn2){ref-type="fn"}       ---         ---                      ---
  Sex (male/female)                     0.987                            −0.380--0.341        0.944                                  ---         ---                      ---
  Tumour size (\< 30 mm/31 mm\<)        2.078                            0.187--1.173         0.012                                 1.616   0.931--2.540                 0.083
  Histology (well, moderate/others)     2.11                             0.227--1.463         0.003[a](#t2-fn2){ref-type="fn"}      1.365   0.799--2.820                  0.28
  Serosal invasion (absent/present)     4.218                            0.669--2.879         \<0.001[a](#t2-fn2){ref-type="fn"}    2.788   1.237--11.920   0.009[a](#t2-fn2){ref-type="fn"}
  Lymphatic invasion (absent/present)   3.063                            0.649--1.729         \<0.001[a](#t2-fn2){ref-type="fn"}    2.003   1.214--3.751    0.005[a](#t2-fn2){ref-type="fn"}
  Venous invasion (absent/present)      2.125                            0.391--1.109         \<0.001[a](#t2-fn2){ref-type="fn"}    1.207   0.823--1.763                 0.331
  *PVT-1* expression (low/high)         2.958                            0.314--2.524         0.002[a](#t2-fn2){ref-type="fn"}      2.532   1.152--10.747   0.016[a](#t2-fn2){ref-type="fn"}

Abbreviations: CI=confidence interval; Moderate=moderately differentiated tubular; RR=relative risk; Well=well differentiated tubular adenocarcinoma.

Statistically significant.
